MTOR and neoplasm: Notably, increasing index I mainly positively correlated with the IC50 of drugs targeting kinases on oncogenic pathways, while index II predominantly sensitized tumor cells to drugs targeting the PI3K/mTOR pathway, kinases, chromosome modifications, and the cell cycle.